Neue Studien: Psoriasis im JDDG

Update vulval dermatology - diagnostics and therapy.

Thu, 29 May 2025 18:10:57 +0000

The vulva is a periorificial skin area and as such represents a transitional zone with unique functional and physiological characteristics. Knowledge of its anatomy is limited among both the general population and healthcare professionals, and unrealistic expectations of normal proportions are common. Ignorance of anatomical variations can cause unnecessary anxiety. In Germany, specialists in gynecology and obstetrics most commonly treat neoplastic vulvar dermatoses, while chronic inflammatory dermatoses commonly affecting the female genitalia (such as psoriasis, atopic dermatitis, hidradenitis suppurativa, and vitiligo) are typically treated by dermatologists. Both specialties treat infectious vulvar dermatoses and sexually transmitted infections. Certain dermatoses, such as lichen sclerosus, lichen planus, and lichen simplex chronicus, tend to affect the vulva preferentially; however, terminology can be confusing. Therefore, this article provides basic information on vulvar anatomy and physiology and summarizes recommendations for the diagnosis and management of the most common vulvar dermatoses, with a special focus on chronic inflammatory dermatoses, to provide a useful guide for all involved specialists in daily practice. Interdisciplinary collaboration and the establishment of dedicated consultation hours may help to improve the clinical care of vulvar dermatoses.

Kutane Impfreaktionen

Thu, 29 May 2025 18:10:57 +0000

No abstract supplied.

Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy.

Thu, 29 May 2025 18:10:57 +0000

No abstract supplied.

History, clinical presentation, therapy, and patient reported outcomes of mucosal lichen planus: a cross-sectional study.

Thu, 29 May 2025 18:10:57 +0000

Background and objectives

Mucosal lichen planus (LP) is a chronic inflammatory disease. The patient's journey can be arduous as diagnosis and therapy are challenging.

Patients and methods

In this cross-sectional study, a wide range of characteristics of the patient's journey were assessed and evaluated from a total of 72 patients with mucosal LP who were treated in the dermatology departments of six German university medical centers between 02/2022 and 07/2023.

Results

On average, 18.1 months elapsed between the onset of symptoms and diagnosis. Until the correct diagnosis was made, an average of 3.1 different physicians of the same or different specialties were consulted. 28.1% of patients also had cutaneous involvement. Therapeutically, 68% of patients received at least one systemic drug. Both topical (90%, 65/72) and systemic (oral, 50% of patients, 36/72; intravenous, 33%, 24/72) glucocorticoids were most frequently used. Systemic agents were most often discontinued due to ineffectiveness (46%, 50/110). Satisfaction with treatment was highest for intravenous and topical glucocorticoids (moderate to high satisfaction: 59% and 36%, respectively), and lowest for retinoids with 8%.

Conclusions

This study indicates that there might be a lack of diagnostic awareness among physicians and the unmet need for effective systemic treatment options.

Morbus‐Grover‐artige Muster in der Frühphase der Pityriasis rubra pilaris

Thu, 29 May 2025 17:51:46 +0000

No abstract supplied.

Cutaneous reactions to vaccination.

Thu, 29 May 2025 17:51:46 +0000

Vaccination is a fundamental principle of preventive health care. Administration of the vaccine, which contains the antigen(s) of a pathogen, activates the immune system and provides protection against infection. The immunogenicity and allergenicity of a vaccine may lead to various adverse reactions, depending on the responsiveness and susceptibility of the vaccinated individual. Cutaneous adverse events are among the most common and can manifest as various local or generalized vaccination reactions. Understanding their pathogenesis and clinical manifestations is essential for therapy, for further diagnostic clarification if necessary, and for managing any booster vaccination that may be required. Appropriate dermatological expertise therefore plays a crucial role in managing patients with a history of vaccination reactions.

Anamnese, klinische Merkmale, Therapie und patientenberichtete Ergebnisse bei Lichen ruber mucosae: Eine Querschnittsstudie

Thu, 29 May 2025 17:51:46 +0000

No abstract supplied.

Wiederbehaarung bei einem Patienten mit Alopecia universalis und Psoriasis vulgaris unter Deucravacitinib‐Therapie

Thu, 29 May 2025 17:51:46 +0000

No abstract supplied.

Indikation zur Systemtherapie bei Psoriasis: Kommentierte Checkliste für die Praxis

Thu, 29 May 2025 17:51:46 +0000

No abstract supplied.

Tofacitinib treatment for acquired reactive perforating collagenosis.

Thu, 29 May 2025 17:51:46 +0000

No abstract supplied.

Epidemiology of generalized pustular psoriasis in Germany: Analyzing factors influencing prevalence estimates health insurance data.

Thu, 29 May 2025 17:51:46 +0000

Background and objectives

Generalized pustular psoriasis (GPP) is a rare, chronic, potentially life-threatening skin disease. We aimed to establish criteria to accurately approximate GPP prevalence in Germany.

Methods

A retrospective analysis of the WIG2 health claims database (1/1/2016-31/12/2020) was conducted. Patients aged ≥ 12 years continuously enrolled in their statutory health insurance with one inpatient or confirmed outpatient diagnosis code for GPP (International Classification of Diseases, 10^th Revision [ICD-10] L40.1) were included. Scenarios with increasingly strict criteria were used to identify the GPP population.

Results

From 2016-2020, 5,236 potential GPP cases were identified based on a recorded GPP diagnosis. The scenario of ≥ 1 GPP diagnosis yielded the highest prevalence (336-390 patients/million) followed by > 1 GPP diagnosis in ≥ 2 quarters (189-288 patients/million); scenarios resulting in the lowest prevalence were diagnosis in ≥ 2 quarters AND two independent diagnoses (17-28/million) and diagnosis in ≥ 2 quarters AND two independent diagnoses or diagnosis by a specialist AND potential flare (58-61 patients/million).

Conclusions

This study suggests that diagnosis in ≥ 2 quarters by a specialist or two independent physicians may be the most clinically robust and reliable criteria for estimating GPP prevalence; therefore, 50-100 patients/million may represent a reasonable prevalence estimate range for Germany.

Successful treatment of subacute cutaneous lupus erythematosus with the TYK-2 inhibitor deucravacitinib in a patient with concomitant psoriasis vulgaris.

Thu, 29 May 2025 17:51:46 +0000

No abstract supplied.

IL-17 and IL-23 inhibitors dose spacing in adult psoriatic patients: a real-world pilot study.

Thu, 29 May 2025 17:51:46 +0000

Background and objectives

De-escalation strategies of biologics in psoriasis treatment are widespread in clinical practice. Dose spacing consists of de-escalating the time range between biological drug injections.

Patients and methods

Major objectives were: to describe trends in mean PASI, PASI 100, 90, and ≤ 1 from baseline to 12 months after dose spacing, provide drug survival analysis of dose-spaced regimens, and concurrently describe phenotypic characteristics related to the selection of patient candidates for therapeutic dose spacing. A pre-post analysis was made between mean PASI at dose spacing and baseline, and after 3, 6, 9, and 12 months following dose spacing.

Results

Of 1,144 patients treated with IL-23 or IL-17 inhibitors, 61 patients underwent dose spacing. They presented with lower mean baseline Body Mass Index (BMI) (p = 0.011) and PASI (Psoriasis Area Severity Index) (p = 0.044) and were more frequently bio-experienced (p = 0.033). 12 months after dose spacing 42.9%, 85.7%, and 92.9% of observed patients achieved PASI 100, 90, and ≤1. There were no significant differences in mean PASI between dose spacing and subsequent time points. The dose spacing survival was 70% at 1 year.

Conclusions

Therapeutic modulation, such as dose spacing, is an effective strategy for most psoriasis patients, resulting in a clear or almost clear skin response that is maintained over time.

Epidemiologie der generalisierten pustulösen Psoriasis in Deutschland: Analyse von Einflussfaktoren auf Prävalenzschätzungen aus Leistungsdaten der Krankenkassen

Thu, 29 May 2025 17:51:46 +0000

No abstract supplied.